Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
A triple-action Formula for comprehensive respiratory relief
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Subscribe To Our Newsletter & Stay Updated
